Skip to main content

The Importance of Early Detection of Non-Alcoholic Fatty Liver Disease

Echosens is proud to join the American Liver Foundation in observance of Liver Cancer Awareness Month. An estimated 30,000 Americans will die of liver cancer this year and Echosens’ urges you to know your risk.

Risk factors include hepatitis B, hepatitis c, fatty liver associated with obesity and diabetes, excessive alcohol use, certain metabolic diseases and other conditions that cause liver failure or cirrhosis. If you have any of these factors you are at risk of liver cancer. Particularly concerning is the silent epidemic afflicting millions of Americans – non-alcoholic fatty liver disease and its more severe form non-alcoholic steatohepatitis or NASH, which is projected to become the leading cause for liver transplants by 2030.

While we advocate for liver patients with all liver diseases, NASH and NAFLD are a growing area of concern for us. Between 30 and 40 percent of Americans are living with this potentially deadly liver disease with no detectable symptoms, highlighting the need to empower people to understand their risk and take steps to keep their liver health.

Thomas NealonPresident & CEO, American Liver Foundation

Today, early detection of NAFLD can help to prevent more serious conditions, as Jon Gingrich, CEO, Echosens North America, says


The good news is that early detection of NAFLD can help to prevent more serious conditions. NAFLD is one of the most common causes of liver disease in the U.S., concurrent with accelerating rates of obesity and diabetes, and yet a lack of awareness regarding symptoms and risk factors continues to fuel this silent epidemic. An assessment with FibroScan, technology that quickly and non-invasively measures liver fat, can detect NAFLD in its earliest stages - and potentially prevent the eventual development of liver cancer.

This October, we urge all Americans and health care professionals to join us in raising awareness about the impact of liver disease and liver cancer. A growing number of primary care physicians now offer an examination with FibroScan as part of a standard work-up to provide rapid, consistent results so that they can make the most informed treatment decisions. This enables them to rule out the need for an expensive and often painful liver needle biopsy or other invasive, expensive testing.

Jon GingrichCEO, Echosens North America

A painless five-minute examination, FibroScan quickly provides a quantitative assessment of liver stiffness and fat at the point of care. FibroScan is recognized worldwide as the reference for non-invasive liver diagnosis supported with more than 2000 peer reviewed publications and 40 guideline recommendations.


Learn more about FibroScan technology
Female technician explaining results after using the FibroScan Mini+ 430 to a female patient who is sitting on a table